

Session III: Diversity Maturity Model Breakout Discussions

Maturity Models

What are they?

- A subjective, yet structured way to evaluate progress
- A holistic view of the major areas that are important for progress
- A breakdown of major areas into key elements that tend to be more practical and definable
- A set of levels that, while based on an overarching concept of attainment, are specifically defined for each key element.


Why use them?

- Provide a broad approach to the topic necessary for success
- Give practical ways to
 - Measure in the absence of hard metrics
 - Establish goals
 - Gain organizational buy-in

Diversity Maturity Model

Purpose:

- Provide a guide for research organizations to assess their current organizational infrastructure for increasing diversity in clinical trials, as well as to identify a desired future state

 Meant to provide broad considerations, not technical details

Breakout Session Topics



Group 1: Scientific Disease Level Strategy



Group 2: Community & Patient Engagement



Group 3: Measurement of Impact

Maturity Model Breakout Sessions

- ▶ **3:05 p.m.:** *Topic introduction & opening general questions or comments on maturity model section*
- ▶ **3:15 p.m.** *Discussion questions*
- ▶ **3:50** *Moderators will enter key points into Mentimeter survey*
- ▶ **3:55** *Return to main meeting for closing*



Breakout Discussion Key Points

Closing, Day 2 Preview

Agenda for October 21 (Day 2)


1:00
p.m. Welcome


1:05
p.m. Session III: Representation in U.S.
Clinical Trials
Richardae Araojo and Kaveeta
Vasisht

1:35
p.m. Session IV: Review of Maturity Model

2:05
p.m. Session V: Breakout Discussions

3:35
p.m. Closing Comments & Adjourn

 Thank you for your participation in Day 1!

 Will incorporate today's content & discussions to finalize breakout session topics on Day 2



CLINICAL
TRIALS
TRANSFORMATION
INITIATIVE

[in](#)  @CTTI_Trials

sara.calvert@duke.edu

THANK YOU

www.ctti-clinicaltrials.org